SCHEMBL18326527

SCHEMBL18326527

Cc1ccc(/C=C/c2cc(O)c(C)c(O)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 5/20 0.64
PTGS2 P35354 4/20 0.64
ALOX5 P09917 4/20 0.64
NFE2L2 Q16236 3/20 0.50
TUBB1 Q9H4B7 2/20 0.48
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48
TUBB8 Q3ZCM7 1/20 0.48
TUBA3E Q6PEY2 1/20 0.48
TUBA1A Q71U36 1/20 0.48
TUBA1C Q9BQE3 1/20 0.48
TUBB6 Q9BUF5 1/20 0.48
TUBB2B Q9BVA1 1/20 0.48
ACE P12821 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18329574 0.87 PTGS1 (0.64) PTGS1PTGS2ALOX5NFE2L2ACE
SCHEMBL5960441 0.83 PTGS1 (0.64) PTGS1PTGS2ALOX5TUBB1TUBB4A
SCHEMBL5960445 0.83 PTGS1 (0.64) PTGS1PTGS2ALOX5TUBB1TUBB4A
SCHEMBL12913068 0.80 PTGS1 (0.71) PTGS1PTGS2ALOX5NFE2L2TUBB1
SCHEMBL4202763 0.80 PTGS1 (0.71) PTGS1PTGS2ALOX5NFE2L2TUBB1
SCHEMBL4202762 0.80 PTGS1 (0.71) PTGS1PTGS2ALOX5NFE2L2TUBB1
SCHEMBL24222559 0.79 TUBB1 (0.57) PTGS1PTGS2ALOX5TUBB1LCK
(E)-1,2-Di-P-Tolylethene SCHEMBL1793692 0.78 NFE2L2 (0.74) PTGS1PTGS2ALOX5NFE2L2TUBB1
SCHEMBL318786 0.78 NFE2L2 (0.74) PTGS1PTGS2ALOX5NFE2L2TUBB1
(E)-1,2-Di-P-Tolylethene SCHEMBL1305582 0.78 NFE2L2 (0.74) PTGS1PTGS2ALOX5NFE2L2TUBB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160367693-A1 Selective Arylation of Dichalcogenides in Biomolecules NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160367693-A1 Selective Arylation of Dichalcogenides in Biomolecules SCLY, SELENOI, TPO PTGS1 4762/4885PTGS2 4677/4885ALOX5 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.